GSK-3beta 詳細
Molecule Name
Glycogen synthase kinase-3 beta
分子の別称
GSK3B,Glycogen synthase kinase-3 beta
Drug Development Progress
治験薬の数4
市販薬剤の数0
研究＆開発段階Phase 3 Clinical
ターゲットの別称
EC 2.7.11，EC:2.7.11.26，EC:2.7.11.1，Serine/threonine-protein kinase GSK3B，Glycogen synthase kinase-3 beta，GSK3B，Glycogen Synthase Kinase 3 Beta，GSK-3 Beta，GSK3beta Isoform，EC 2.7.11.26，EC 2.7.11.1
バックグランド
Glycogen synthase kinase-3 (GSK-3) is a pivotal molecule in the development of Alzheimer's disease (AD). GSK-3beta is involved in the formation of paired helical filament (PHF)-tau, which is an integral component of the neurofibrillary tangle (NFT) deposits that disrupt neuronal function, and a marker of neurodegeneration in AD.
GSK-3beta 製品リスト
You Have Viewed 0 Of 0 Results
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Tideglusib | NP-12; AMO-02; NP-031112 | Phase 3 Clinical | Noscira Sa | Alzheimer Disease; Amyotrophic Lateral Sclerosis; Autism Spectrum Disorder; Cardiomyopathies; Myotonic Dystrophy | 詳細 |
| Ruboxistaurin Mesilate Hydrate | LY-333531; REC 3599; SM 030 | Phase 2 Clinical | Eli Lilly And Company | Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic macular oedema; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Gangliosidoses, GM2; Heart Failure; Hyperpigmentation; Melanosis | 詳細 |
| Elraglusib | 9-ING-41 | Phase 2 Clinical | Actuate Therapeutics Inc, Northwest University, University Of Illinois At Chicago | Adenocarcinoma; Bone metastases; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Adenoid Cystic; Colorectal Neoplasms; Dermatofibrosarcoma; Diffuse Intrinsic Pontine Glioma; Glioma; Hemangiosarcoma; Kidney Neoplasms; Leiomyosarcoma; Leukemia-Lymphoma, Adult T-Cell; Liposarcoma; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Meningioma; Neoplasm Metastasis; Neoplasms; Neuroblastoma; Osteosarcoma; Pancreatic Neoplasms; Primary Myelofibrosis; Rhabdomyosarcoma; Salivary Gland Neoplasms; Sarcoma; Sarcoma, Ewing; Sarcoma, Synovial | 詳細 |
| Asnuciclib | CDKI-73; LS-007; QHRD-107 | Phase 2 Clinical | Shandong University, University Of South Australia | Leukemia, Myeloid, Acute | 詳細 |